

Best of ASCO 2013 in Japan プログラム

as of 17 June / 2013

※本セミナーでとりあげる演題は、2013年5月31日～6月4日に開催される米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のプログラム委員会が選定したものです。但し、IDに * 印のある演題は日本臨床腫瘍学会のプログラム委員会が独自で選定したものです。

7月6日（土曜日）

Time	講師	司会	ASCO演題		
9:00	開場		ID	Abstract Title	Author
10:00-10:05	Welcome & Introduction 秋田 弘俊 北海道大学				
10:05-10:25	血液 Leukemia, Myelodysplasia, and Transplantation 小林 幸夫 国立がん研究センター中央病院	照井 康仁 がん研有明病院	7001	Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.	Michael W. N. Deininger, MD, PhD
			7004	Obinutuzumab (GA101) plus chlorambucil (Cib) or rituximab (R) plus Cib versus Cib alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.	Valentin Goede
10:25-10:35	Discussion: Q&A				
10:35-11:00	血液 Lymphoma and Plasma Cell Disorders 鈴木 達也 名古屋第二赤十字病院	飯田 真介 名古屋市立大学	8503	Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: A prospective study to compare entecavir and lamivudine.	He Huang
			8509	Melphalan/prednisone/enalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.	Mario Boccadoro, MD
			8510	MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).	Jesus San Miguel, MD, PhD
11:00-11:10	Discussion: Q&A				
11:10-11:45	脳脊髄腫瘍 Central Nervous System Tumors 成田 善孝 国立がん研究センター中央病院	南 博信 神戸大学	1	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).	Mark R. Gilbert
			2003	Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825.	Terri S. Armstrong, PhD, ANP-BC, FAANP
			LBA2000	Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.	Ulrich Herrlinger
			2001	A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.	Walter Taal
11:45-11:55	Discussion: Q&A				
11:55-12:15	Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics 清水 俊雄 近畿大学	朴 成和 聖マリアンナ医科大学	2500	A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.	Geoffrey Shapiro, MD, PhD
			2531	Safety, pharmacokinetics, and preliminary activity of the α -specific PI3K inhibitor BYL719: Results from the first-in-human study.	Ana M. Gonzalez-Angulo, MD, MSc
12:15-12:25	Discussion: Q&A				
12:25-12:40	Break 15分				
12:40-13:40	【ランチョンセミナー】 山田 康秀 国立がん研究センター中央病院	兵頭 一之介 筑波大学	進行再発大腸癌の最適な治療方法 – ASCO2013 の報告を踏まえて – 中外製薬株式会社		
13:40-13:55	Break 15分				
13:55-14:30	Melanoma / Skin Cancers 扇田 信 聖路加国際病院	関根 郁夫 千葉大学	9003	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).	Richard D. Carvajal, MD
			9009	Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (1 of 3)	Antoni Ribas, MD
			9010	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (2 of 3)	Omid Hamid, MD
			9011	Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. (3 of 3)	Jeffrey S. Weber
			9012	Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).	Jedd D. Wolchok, MD, PhD
			LBA9008	OPTIM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.	Robert Hans Ingemar Andtbacka, MD
14:30-14:40	Discussion: Q&A				
14:40-15:15	Patient and Survivor Care 高野 利実 虎の門病院	秋田 弘俊 北海道大学	9503	A multicenter, randomized, double-blinded, placebo-controlled trial of modafinil for lung cancer-related fatigue: Dose response and patient satisfaction data.	Kate Fife, MD, FRCP, FRCR, FRANZCR
			LBA9514	Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).	Matti S. Aapro, MD
			2006	Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors.	Stephen R. Rapp, Ph.D.
			9621*	Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.	Hironobu Hashimoto
15:15-15:25	Discussion: Q&A				
15:25-15:40	Coffee Break 15分				
15:40-16:05	肺がん - Non-small Cell Cytotoxics 瀬戸 貴司 国立病院機構九州がんセンター	後藤 功一 国立がん研究センター東病院	7501	A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.	Jeffrey D Bradley, MD
			7503	Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).	Miklos Pless, MD
			LBA8003	Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).	Ralph Zinner, MD
16:05-16:15	Discussion: Q&A				
16:15-16:50	肺がん - Non-small Cell Molecular target 岡本 勇 九州大学病院	中川 和彦 近畿大学	8008	Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).	David R. Spigel, MD
			LBA8005	Randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).	Chiara Lazzari
			LBA8011	Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial.	Martin Reck
			8006*	Randomized Phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) who have wild-type or mutant EGFR: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)	Yoshio Okano
16:50-17:00	Discussion: Q&A				
17:00-17:15	Break 15分				
17:15-18:00	【イブニングセミナー】 大川 伸一 神奈川県立がんセンター	朴 成和 聖マリアンナ医科大学	肺癌がん化学療法の最新の知見～ASCO2013を受けて～ 大鵬薬品工業		

7月7日（日曜日）

Time	講師	司会	ASCO演題		
8:30	開場		ID	Abstract Title	Author
9:00-9:30	婦人科がん 原野 謙一 日本医科大学武蔵小杉病院	田村 研治 国立がん研究センター中央病院	3	Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.	Krishnansu Sujata Tewari, MD
			LBA5501	A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicentre Italian Trials in Ovarian Cancer (MITO-7)– European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10)–Gynecologic Cancer Intergroup (GCIg) trial.	Sandro Pignata, MD, PhD
			LBA5503	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).	Andreas Du Bois, MD
9:30-9:40	Discussion: Q&A				
9:40-10:15	消化器がん - Gastrointestinal Cancer 設楽 紘平 国立がん研究センター東病院	濱口 哲弥 国立がん研究センター中央病院	3504	A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.	John Neil Primrose, MD, FRCS
			LBA3506	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).	Volker Heinemann, MD
			LBA4001	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGIC trial.	J. Randolph Hecht, MD
			LBA4002	SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.	Kazuhiro Yoshida, MD, PhD
10:15-10:25	Discussion: Q&A				
10:25-10:55	消化器がん - Hepatobiliary / Pancreas Cancer 福富 晃 静岡県立静岡がんセンター	馬場 英司 九州大学	4005	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.	Daniel D. Von Hoff, MD
			4008	JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer.	Akira Fukutomi, MD
			LBA4003	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.	Pascal Hammel, MD, PhD
10:55-11:05	Discussion: Q&A				
11:05-11:35	泌尿器がん 内野 慶太 国立病院機構九州医療センター	中川 昌之 鹿児島大学	LBA4500	A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.	Karim Fizazi, MD
			LBA4510	Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.	Abdenour Nabid, MD, FRCP®
			5009	Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).	Dana E. Rathkopf, MD
11:35-11:45	Discussion: Q&A				
11:45-12:05	Break 20分				
12:05-13:05	【ランチョンセミナー】 佐々木 治一郎 北里大学病院化学療法センター	大江 裕一郎 国立がん研究センター東病院	Ⅳ期肺癌の薬剤選択規定因子 ～年齢、PS、組織型、遺伝子変異、患者の好み～ 日本イーライリリ－株式会社		
13:05-13:25	Coffee Break 20分				
13:25-13:40	頭頸部がん 清田 尚臣 神戸大学	田原 信 国立がん研究センター東病院	4	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.	Marcia S. Brose, MD, PhD
13:40-13:50	Discussion: Q&A				
13:50-14:30	乳がん - Molecular target 佐治 重衡 京都大学	勝俣 範之 日本医科大学武蔵小杉病院	5	aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.	Richard G. Gray, MA, MSc
			500	Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.	Lisa A. Carey, MD
			511	Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).	Fabrice Andre, MD, PhD
			505*	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).	Ruth O'Regan, Mustafa Ozguroglu
			LBA509	Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR ⁺), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.	Gabriel N. Hortobagyi, MD, FACP
14:30-14:40	Discussion: Q&A				
14:40-15:15	乳がん - Cytotoxics / Local Therapy 松本 光史 兵庫県立がんセンター	清水千佳子 国立がん研究センター中央病院	1000	10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.	Thomas B. Julian, MD
			1004	A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto).	Gunter Von Minckwitz
			1007	Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.	Lawrence N. Shulman, MD
			LBA1001	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023).	Emiel J. Rutgers, MD, PhD
15:15-15:25	Discussion: Q&A				
15:25-15:35	Closing Remarks 南 博信 神戸大学				